Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study.

Molecular oncology - 1 Jan 2022

Schou Nørøxe Dorte, Flynn Aidan, Westmose Yde Christina, Østrup Olga, Cilius Nielsen Finn, Skjøth-Rasmussen Jane, Brennum Jannick, Hamerlik Petra, Weischenfeldt Joachim, Skovgaard Poulsen Hans, Lassen Ulrik

Abstract excerpt

Treatment of glioblastoma (GBM) remains a challenging task, with limited treatment options, none offering a cure. Immune therapy has proven effective across different cancers with remarkable response rates. Tumor mutational burden (TMB) is a marker of response, but technical and methodological differences in TMB estimates have made a proper assessment and comparison challenging. Here, we analyzed a prospective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Glioblastoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Temozolomide

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 34018316
DOI: 10.1002/1878-0261.13015
PMCID: PMC8732341

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study.PMID 34018316Read ↗

Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma.Semantic proximity Read ↗

GBMPurity: A machine learning tool for estimating glioblastoma tumor purity from bulk RNA-sequencing dataSemantic proximity Read ↗

DNA Methylation-Based Deconvolution Study of Glioblastoma Heterogeneity and Cell Types Associated with Patient SurvivalSemantic proximity Read ↗

Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.Semantic proximity Read ↗

DNA Methylation-Based Deconvolution Sheds Light on Glioblastoma Heterogeneity and Cell-Type Composition Associated with Patient SurvivalSemantic proximity Read ↗

High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models.Semantic proximity Read ↗

Of Context, Quality, and Complexity: Fine-Combing Tumor Mutational Burden in Immunotherapy-Treated Cancers.Semantic proximity Read ↗

All-FIT: Allele-Frequency-based Imputation of Tumor Purity from High-Depth Sequencing DataSemantic proximity Read ↗

Identifying differentially methylated sites in samples with varying tumor puritySemantic proximity Read ↗

All-FIT: allele-frequency-based imputation of tumor purity from high-depth sequencing data.Semantic proximity Read ↗

RF_Purify: a novel tool for comprehensive analysis of tumor-purity in methylation array data based on random forest regressionSemantic proximity Read ↗

Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.